Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know

Company Performance - Johnson & Johnson (JNJ) closed at $209.72, with a daily increase of +2.61%, outperforming the S&P 500's gain of 0.16% [1] - Prior to this trading day, JNJ shares had decreased by 3.4%, underperforming the Medical sector's gain of 2.84% and the S&P 500's gain of 1.89% [1] Upcoming Earnings - The upcoming earnings report is expected on January 21, 2026, with an anticipated EPS of $2.52, reflecting a 23.53% increase year-over-year [2] - Revenue is projected to be $24.11 billion, indicating a 7.06% increase compared to the same quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at $10.86 per share, representing an increase of +8.82%, while revenue is expected to remain flat at $93.7 billion [3] Analyst Forecasts - Recent revisions to analyst forecasts are crucial, as upward revisions indicate positive sentiment regarding the company's business operations and profit generation capabilities [4] - Adjustments in estimates are linked to stock price performance, suggesting that investors can benefit from tracking these changes [5] Zacks Rank and Valuation - Johnson & Johnson currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 17.8, which is higher than the industry's Forward P/E of 15.26 [6] - The company has a PEG ratio of 2.1, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.59 [7] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 185, placing it in the bottom 25% of over 250 industries [7][8] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]